Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
Sen. Richardson presents SB 10 89 to expand GLP‑1 coverage for state employees; bill moved to suspense file
Summary
Sen. Richardson told the Senate Appropriations Committee SB 10 89 would reduce CalPERS medical costs by expanding access to GLP‑1 weight‑loss medications for state employees meeting BMI criteria and would direct CalRx to pursue production or acquisition of at least one GLP‑1 drug. The committee placed the bill on the suspense file for further work and amendments.
Sen. Richardson presented SB 10 89 to the Senate Appropriations Committee as an effort to reduce medical costs for CalPERS by expanding access to GLP‑1 weight‑loss drugs for state public employees meeting specified BMI thresholds.
"The rising prevalence of chronic weight disease represents a substantial financial burden," Richardson said, arguing that ensuring state employees at a BMI of 30 or higher have access to weight‑loss drugs including GLP‑1 medications could reduce long‑term costs tied to obesity‑related conditions such as diabetes and certain cancers. Richardson also said SB 10 89 would require CalRx to enter partnerships to produce or acquire at least one GLP‑1 medication.
Richardson told the committee she expects to work with industry and members to refine amendments. No Department of Finance representative was present for fiscal comment during the hearing.
The committee moved SB 10 89 to the suspense file without objection.
Next steps: The author indicated forthcoming amendments; the bill is on the suspense file pending further fiscal and policy work.
